RRP Foundation position statement.1,2
Navigating access
Papzimeos SUPPORT
Precigen is dedicated to supporting your patients, your practice, and you. That’s why we’ve created Papzimeos SUPPORT to help ensure you have all the information you need for access, reimbursement, and more.
PAPZIMEOS has broad coverage across plans, with dedicated support to help:
- Conducting benefits investigations and communicating payer requirements to the prescriber
- Determining patient financial responsibility and evaluating patients for copay assistance programs
If you are using Papzimeos SUPPORT as a specialty pharmacy, you will receive additional support, such as:
- Help providing information on prior authorization requirements and other documentation for payers Download this guide to navigate the access and reimbursement process
- Support in navigating peer-to-peer reviews and appeals (if needed)
- Ordering PAPZIMEOS and coordinating delivery to the site of administration Download this guide to order and receive PAPZIMEOS
- Support in navigating peer-to-peer reviews and appeals (if needed)
Commercial and government insurers all have different coverage and payment policies for medications and services. Check directly with the patient’s insurer(s) to verify specific requirements for PAPZIMEOS.
Enrolling your patients
Accessing PAPZIMEOS starts with the completion of the Papzimeos SUPPORT Enrollment Form. Before completing the form, make sure that you have information available about the patient’s clinical history and insurance coverage, as well as the site of care where they will receive PAPZIMEOS treatments. When completing the form, ensure all sections are thoroughly filled out to avoid disruptions in the access process and delays in patient care.
Access the Papzimeos SUPPORT Healthcare Professional
Enrollment Form online
You and your office can fill out all the information necessary for your patient and
submit it online. Biologics will contact your patient to retrieve their signature.
You can also download the enrollment form. Complete and fax the form to (833) 813‑8580.
For questions or support, call (866) 827‑8180, Monday to Friday, 8 AM to 8 PM ET.
Copay support for eligible patients
The Papzimeos SUPPORT Copay Program offers savings that may reduce out-of-pocket costs per calendar year for eligible commercially insured patients, subject to certain terms and conditions.
Eligible patients may pay as little as $0 out-of-pocket for PAPZIMEOS. There are no income requirements to participate in the program.*
Eligible patients
may pay as little as:
$0
out-of-pocket
Evaluation of eligibility for the Papzimeos SUPPORT Copay Program begins with the submission of the Papzimeos SUPPORT Enrollment Form. Once enrolled, patient eligibility will be determined and communicated to the patient.
Patients will need to be enrolled in Papzimeos SUPPORT to participate in the Papzimeos SUPPORT Copay Program. See below for the full terms and conditions of the Papzimeos SUPPORT Copay Program.
Papzimeos SUPPORT Copay Program Terms and Conditions
The Papzimeos SUPPORT Copay Program is for eligible patients enrolled in Papzimeos SUPPORT, who are commercially insured and not covered under government insurance programs, such as Medicare, Medicaid, Veterans Affairs/Department of Defense (VA/DoD), or TRICARE. The program assists only with the cost of PAPZIMEOS and its administration, up to the program maximum. It does not assist with the cost of other administrations, medicines, procedures, or other visits. Patients receiving assistance through another program or foundation are not eligible for the program. Precigen reserves the right to modify or terminate the program at any time without notice. If I seek reimbursement under the Papzimeos SUPPORT Copay Program on behalf of my patient(s), I certify the following for each request: (i) I have provided true and accurate information; (ii) the expenses requested for reimbursement are eligible under the program and were actually incurred and not paid by the patient or any party; (iii) the patient is not insured under Medicare, Medicaid, VA/DoD, TRICARE, or any other federal or state government-funded program and has received PAPZIMEOS for the FDA-approved indication; (iv) I have not requested or received, and will not request or receive, any payments from the patient or any party for the amounts I seek reimbursement under the program.
INDICATION
PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of recurrent respiratory papillomatosis in adults.
Indication and Important Safety Information
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Injection-Site Reactions: Injection-site reactions have occurred with PAPZIMEOS injection. Monitor patients for local site reactions for at least 30 minutes after the initial treatment.
Thrombotic Events: Thrombotic events may occur following administration of adenoviral vector-based therapies. Monitor patients for signs and symptoms of thrombotic events and treat events according to clinical practice.
ADVERSE REACTIONS
The most commonly reported adverse reactions (≥5% of patients) in PAPZIMEOS-treated patients were injection site reactions, fatigue, chills, pyrexia, myalgia, nausea, headache, tachycardia, diarrhea, vomiting, and hyperhidrosis.
USE IN SPECIFIC POPULATIONS
Pregnancy: There are no available data with PAPZIMEOS in pregnant women.
Lactation: There is no information available on the presence of PAPZIMEOS in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PAPZIMEOS and any potential adverse effects on the breastfed child from PAPZIMEOS or from the underlying maternal condition.
Pediatric Use: The safety and effectiveness of PAPZIMEOS have not been established in pediatric patients.
Geriatric Use: Clinical studies of PAPZIMEOS did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients.
Please see full Prescribing Information.
INDICATION
PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of recurrent respiratory papillomatosis in adults.
Indication and
Important Safety Information
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Injection-Site Reactions: Injection-site reactions have occurred with PAPZIMEOS injection. Monitor patients for local site reactions for at least 30 minutes after the initial treatment.
Thrombotic Events: Thrombotic events may occur following administration of adenoviral vector-based therapies. Monitor patients for signs and symptoms of thrombotic events and treat events according to clinical practice.
ADVERSE REACTIONS
The most commonly reported adverse reactions (≥5% of patients) in PAPZIMEOS-treated patients were injection site reactions, fatigue, chills, pyrexia, myalgia, nausea, headache, tachycardia, diarrhea, vomiting, and hyperhidrosis.
USE IN SPECIFIC POPULATIONS
Pregnancy: There are no available data with PAPZIMEOS in pregnant women.
Lactation: There is no information available on the presence of PAPZIMEOS in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PAPZIMEOS and any potential adverse effects on the breastfed child from PAPZIMEOS or from the underlying maternal condition.
Pediatric Use: The safety and effectiveness of PAPZIMEOS have not been established in pediatric patients.
Geriatric Use: Clinical studies of PAPZIMEOS did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients.
Please see full Prescribing Information.
INDICATION
PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of recurrent respiratory papillomatosis in adults.
Important Safety Information
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Injection-Site Reactions: Injection-site reactions have occurred with PAPZIMEOS injection. Monitor patients for local site reactions for at least 30 minutes after the initial treatment.
Thrombotic Events: Thrombotic events may occur following administration of adenoviral vector-based therapies. Monitor patients for signs and symptoms of thrombotic events and treat events according to clinical practice.
ADVERSE REACTIONS
The most commonly reported adverse reactions (≥5% of patients) in PAPZIMEOS-treated patients were injection site reactions, fatigue, chills, pyrexia, myalgia, nausea, headache, tachycardia, diarrhea, vomiting, and hyperhidrosis.
USE IN SPECIFIC POPULATIONS
Pregnancy: There are no available data with PAPZIMEOS in pregnant women.
Lactation: There is no information available on the presence of PAPZIMEOS in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PAPZIMEOS and any potential adverse effects on the breastfed child from PAPZIMEOS or from the underlying maternal condition.
Pediatric Use: The safety and effectiveness of PAPZIMEOS have not been established in pediatric patients.
Geriatric Use: Clinical studies of PAPZIMEOS did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger patients.
Please see full Prescribing Information.
- References:
- PAPZIMEOS. Package insert. Precigen, Inc; 2025.
- Best SR, Friedman AD, Rosen CA, et al. Recurrent Respiratory Papillomatosis Foundation position statement on the management of adults with RRP. Laryngoscope. 2026;136(suppl 4):S7–S17. doi:10.1002/lary.70379